Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

NCT00635791 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumour
Renal Cell Carcinoma
Non Small Cell Lung Carcinoma

Interventions

DRUG: Sorafenib
DRUG: Vorinostat

Sponsor

University of Colorado, Denver

Collaborators

[object Object]
[object Object]